Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03081858 | Completed Phase 1 Results FDA Drug

• 1 other identifier: TD-001
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 5

Brief Summary

This is a single-arm, phase 1/2a study of formulated paclitaxel in subjects with low-grade, noninvasive papillary carcinoma (stage Ta) of the bladder. Part 1 of the study will enroll 6 subjects (3 per cohort) with low-grade, stage Ta transitional cell carcinoma (TCC) of the bladder who will receive escalating doses of paclitaxel formulated as TSD-001 every 2 weeks for 6 treatments until Dose Limiting Toxicity (or until the Maximum Deliverable Dose) is observed (Maximum Tolerated Dose established). Part 2 of the study will enroll an additional 10 subjects with low-grade, stage Ta (uni-or multifocal) TCC of the bladder who will receive weekly TSD-001 for 6 weeks at the highest nontoxic dose (i.e., MTD) established in part 1 of the study. May meet definition of low grade without histological tissue diagnosis if on cystoscopic assessment they have a solitary papillary tumor. Part 3 of the study will continue to track subjects enrolled in Parts 1 and 2 to determine rates of disease-free survival.

Conditions

Bladder Cancer Cell Transitional; Non-Muscle Invasive Bladder Cancer; Bladder Cancer; Urinary Bladder; Transitional Cell Carcinoma of the Bladder; Urinary Bladder Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Urinary Bladder Diseases; Urologic Diseases

Keywords

NMIBC; Paclitaxel; Antineoplastic Agents; Bladder Cancer

Outcome Measures

Primary Outcomes (2)

• Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD)

  Dose immediately preceding the dose at which DLT occurs or when a MDD is reached.

  12 weeks

• Part 2: Marker Lesion Response Rate

  Determine the marker lesion response rate at final assessment visit for subjects that received the MDD established in part 1.

  12 weeks (Cohort 1) or 15 weeks (Cohort 2)

Secondary Outcomes (2)

• Part 1: Determine Paclitaxel Concentrations

  10 weeks

• Part 2: Determine Paclitaxel Concentrations

  Week 2 (pre and post dose)

Other Outcomes (1)

• Part 3: Rates of Recurrence/Disease-Free Survival in Part 1 Subjects Only at 12 and 24 Months

  2 years

Study Arms (3)

TSD-001 Administration Part 1, Cohort 1

EXPERIMENTAL

Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged \[greater than 14 days\] grade 2 toxicity) is observed.

Drug: TSD-001

TSD-001 Administration Part 1, Cohort 2

EXPERIMENTAL

Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged \[greater than 14 days\] grade 2 toxicity) is observed. If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study.

Drug: TSD-001

TSD-001 Administration Part 2

EXPERIMENTAL

In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route. During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure).

Drug: TSD-001

Interventions

TSD-001 DRUG

Administered via intravesical instillation.

Also known as: Proliposomal Intravesical Paclitaxel

TSD-001 Administration Part 1, Cohort 1; TSD-001 Administration Part 1, Cohort 2; TSD-001 Administration Part 2

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has a diagnosis of low grade (G1 or G2), uni- or multifocal papillary appearing bladder tumor, stage Ta.
• Subject is surgical candidate for TURBT as part of normal NMIBC treatment plan. For part 1, successful completion of TURBT procedure. For part 2, successful completion of cystoscopic assessment/TURBT procedure with one marker lesion left intact; the marker lesion should be \> 0.5 cm and \< 2.0 cm in diameter.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Peripheral neuropathy grade 1 or less.
• Adequate hematological, hepatic, and renal parameters; i.e., hemoglobin \> 10 g/dL, creatinine \< 3.5 mg/dL, bilirubin \< 1.5 mg/dL , and aspartate aminotransferase, alanine aminotransferase \< 50 U/L, and alkaline phosphatase \< 130 U/L.
• All sexually active subjects of reproductive potential are required to use or start using a reliable method of birth control at least 2 weeks prior to study enrollment, throughout the study, and for at least 3 months following completion of study therapy.
• Females of childbearing potential must have a negative pregnancy test within 30 days prior to enrollment. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.
• For male subjects, the digital rectal examination must not be suspicious for carcinoma of the prostate.
• Able to retain bladder instillations for up to 120 minutes (± 15 minutes).

You may not qualify if:

• Has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the subject is to be disease free for at least 5 years. Subjects with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. Subjects will not be excluded for recurrent NMIBC, basal or squamous cell skin cancers, or noninvasive cancer of the cervix.
• Has positive urine cytology for urothelial malignancy at screening.
• Has an active uncontrolled infection, including a urinary tract infection, underlying medical condition, or other serious illness that would impair the ability of the subject to receive protocol treatment.
• Previous intravesical therapy within 6 months of study entry.
• Prior radiation to the pelvis.
• Participated in a previous clinical trial or used any investigational drugs, biologics, or devices within 90 days prior to study treatment or plans to use any of these during the course of the study.
• Has had any previous exposure to paclitaxel or docetaxel in the last 5 years.
• Has or has ever had: upper tract TCC; urethral tumor (prostatic urethra included); any invasive bladder tumor known to be other than tumor Ta, low-grade (G1-G2); any evidence of lymph node or distant metastasis; any bladder tumor with histology other than TCC; or carcinoma in situ (CIS).
• Has a tumor in a bladder diverticulum
• Concurrent treatment with any chemotherapeutic agent.
• History of vesicoureteral reflux.
• An indwelling ureteral stent.
• Has received any pelvic radiotherapy (including external beam and/or brachytherapy.)
• Has a bleeding disorder or a screening platelet count \< 100×109/L.
• Has an active diagnosis of interstitial cystitis.

Sponsors & Collaborators

• Lipac Oncology LLC: lead
• TesoRx Pharma, LLC: collaborator

Study Sites (5)

Urological Associates of Southern Arizona, PC

Tucson, Arizona, 85741, United States

Location

Trovare Clinical Research

Bakersfield, California, 93301, United States

Location

Tower Urology

Los Angeles, California, 90048, United States

Location

Chesapeake Urology Associates

Hanover, Maryland, 21076, United States

Location

Carolina Urologic Research Clinic

Myrtle Beach, South Carolina, 29572, United States

Location

MeSH Terms

Conditions

Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Urinary Bladder Diseases; Urologic Diseases

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Results Point of Contact

• Title: Karl Bean
• Organization: LIPAC Oncology

karl@lipaconcology.com

714-900-4412

Study Officials

• Michael Oefelein, MD

  Lipac Oncology LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 10, 2017
• First Posted: March 16, 2017
• Study Start: May 17, 2018
• Primary Completion: August 27, 2020
• Study Completion: August 5, 2021
• Last Updated: June 27, 2025
• Results First Posted: June 13, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (5)